The New York Mets' one-year tenure with this outfielder was a disaster, and now they'll watch his progress as he heads west.

Nick Madrigal is fighting for a roster spot with the Mets, and it’s unclear how much time he’ll miss after the injury to his ...

Nick Madrigal's first foray into the shortstop position did not go as planned. The Mets infielder suffered a dislocated left shoulder on a slow roller on the infield grass during the first inning of ...

If you are wondering whether Madrigal Pharmaceuticals at around US$499 per share is still good value after a strong multiyear run, you are not alone. The stock has a 7 day return of 0.5% decline, a 30 ...

CONSHOHOCKEN, Pa., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its fourth-quarter and full-year 2025 financial results on ...

Madrigal Pharmaceuticals, Inc. has secured a $500 million senior secured credit facility from Blue Owl Capital to advance its pipeline focused on treating metabolic dysfunction-associated ...

Nick Madrigal dislocated his left shoulder during today’s Spring Training split-squad game between the Mets and Nationals. In the first inning of the game, Madrigal (who was playing shortstop) had to ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it ...

Madrigal Pharmaceuticals is developing resmetirom, a drug for non-alcoholic steatohepatitis and fatty liver disease, with promising trial results. Madrigal has a strong cash position and manageable ...

Nick Madrigal, a utility infielder who came into camp with a good chance of making the Mets out of spring training, will undergo surgery on his fractured left shoulder and is expected to miss the ...

Wondering whether Madrigal Pharmaceuticals might be undervalued or perhaps riding a little too high? You are not alone, as many investors are digging into its numbers to decide if there is real value ...

With the Chicago Cubs fully invested in the shortstop market this offseason, the middle of their infield will probably look vastly different in 2023. Despite a stellar season at shortstop in 2022, ...